Growth Metrics

NovoCure (NVCR) Cash from Investing Activities (2016 - 2026)

NovoCure's Cash from Investing Activities history spans 13 years, with the latest figure at $7.7 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 219.7% to $7.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $451.5 million, a 214.9% increase, with the full-year FY2025 number at $437.3 million, up 411.8% from a year prior.
  • Cash from Investing Activities hit $7.7 million in Q1 2026 for NovoCure, down from $336.3 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for NVCR hit a ceiling of $336.3 million in Q4 2025 and a floor of -$374.4 million in Q2 2024.
  • Historically, Cash from Investing Activities has averaged $20.5 million across 5 years, with a median of $10.2 million in 2024.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 6049.47% in 2022 and later tumbled 2594.39% in 2024.
  • Tracing NVCR's Cash from Investing Activities over 5 years: stood at -$128.1 million in 2022, then skyrocketed by 176.92% to $98.5 million in 2023, then crashed by 122.55% to -$22.2 million in 2024, then soared by 1614.23% to $336.3 million in 2025, then tumbled by 97.7% to $7.7 million in 2026.
  • Business Quant data shows Cash from Investing Activities for NVCR at $7.7 million in Q1 2026, $336.3 million in Q4 2025, and $71.4 million in Q3 2025.